DONALD PARSONS to Antineoplastic Agents
This is a "connection" page, showing publications DONALD PARSONS has written about Antineoplastic Agents.
Connection Strength
0.430
-
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
Score: 0.098
-
Precision Medicine in Pediatric Oncology. Surg Oncol Clin N Am. 2020 01; 29(1):63-72.
Score: 0.088
-
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017 05 01; 109(5).
Score: 0.074
-
Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia. Pediatr Blood Cancer. 2017 05; 64(5).
Score: 0.071
-
Applications of Genomic Sequencing in Pediatric CNS Tumors. Oncology (Williston Park). 2016 May; 30(5):411-23.
Score: 0.069
-
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3? inhibitors in children and adolescents with cancer. Eur J Cancer. 2024 Aug; 207:114145.
Score: 0.030